logo

Do you have Atopic Dermatitis?

Atopic dermatitis (AD) is the most common form of eczema. It is a chronic condition that causes dry, itchy, and inflamed skin. This skin disorder affects individuals of all ages, ethnicities, and all geographic regions worldwide.

We are currently recruiting people aged 18 to 75 years with moderate to severe atopic dermatitis, to participate in an investigational study called the COMPASS 2-AD study.

The COMPASS 2-AD study consists of an injection under the skin every two weeks for 30 weeks. This treatment is experimental. There will be three groups in this study, and if you are eligible to participate, you will be randomly assigned to one of these groups (like drawing numbers from a hat). Everyone who participates in the study will receive both the study drug and the placebo, but the doses and the order in which the drug or placebo is received will vary depending on the group you are assigned to.

Compensation for your time and travel may be available. There will be no cost to you for being considered or for taking part in this study, and you will be provided with all study medication, examinations, and medical care related to the study at no cost to you.

 Join the trial to contribute to the development of this treatment and potentially benefit from its effects.


Visits
Total
Length
Procedures
Study Length
Total
22
Length
Up to 2-3 hours
Procedures
Electrocardiogram, blood draws, urine samples, medical physical exams, medical photographs of skin lesions, answer questions related to the impact of AD on your quality of life, AD severity, and how AD and itch affect you, daily diary completion for tracking your itch severity.
Study Length
Up to 40 weeks. Up to 30 days of screening period, up to 30 weeks of treatment and 6 weeks of follow up period
Summary
We're conducting the COMPASS 2-AD study to determine the safety and effectiveness of different doses of an investigational medication, BFB759, for treating adults with atopic dermatitis. This medication is administered as an injection (similar to a shot) under your skin. There will be three groups in the study. If you are eligible and choose to participate, you'll be randomly assigned to one of these groups (like drawing numbers from a hat). All participants will receive both the study drug and a placebo, but the doses and and the order in which the drug or placebo is received will vary depending on the group you are assigned to. You'll receive the study drug and/or placebo every two weeks for 30 weeks. There will be no cost to you for participating in this study. By joining, you'll contribute to important research and potentially benefit from the treatment.
Rectangle 191

Are you a researcher or representative of a clinical site?

Join our network of clinical sites and be at the forefront of innovation in clinical research.